Back to Crohns Disease And Colitis
NCT00206674
NCT00206674
Who may be able to join
Who might be able to join this trial:
- You have Crohn's disease that is active (causing symptoms) but in a stable condition at the time of screening
- You are able to give yourself an injection, or you have someone who can help you do this
Who may not be able to join:
- You have a colostomy or ileostomy (a surgically created opening in the abdomen for waste removal)
- You are currently taking certain medications that are not allowed as part of this trial (confirm with trial site for the specific list)
- You have had bowel or digestive tract surgery, or a blockage in your bowel, in the last 6 months, or you have surgery planned in the coming months
- You have previously taken this drug, or any similar type of drug, at any point in the past
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 3
Sponsor
Genzyme, a Sanofi Company
Registry
clinicaltrials_gov
Start date
1 September 2004
Est. completion
1 June 2006
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇧🇷 Brazil
🇨🇦 Canada
🇳🇿 New Zealand
🇷🇺 Russia
🇨🇭 Switzerland
🇺🇦 Ukraine
🇬🇧 United Kingdom
17 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Induction of clinical response and/or remission as defined by decrease in CDAI score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.